Barclays Reiterates an 'Overweight' on Human Genome Sciences (HGSI); Lancet Publishes BLISS-52 + Favorable Review
Tweet Send to a Friend
Barclays reiterates an 'Overweight' on Human Genome Sciences (NASDAQ: HGSI), PT $40.
Barclays analyst says, "We are reiterating our rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are reiterating our rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
